<?xml version="1.0" encoding="UTF-8"?>
<p>The recent reduction or removal of reimbursement-restrictions concerning DAA therapy in Europe due to governmental programs and financial competition between pharmaceutical companies opened up new opportunities concerning the realization of these elimination targets[
 <xref rid="pone.0229239.ref017" ref-type="bibr">17</xref>,
 <xref rid="pone.0229239.ref018" ref-type="bibr">18</xref>]. One pangenotypic DAA combination that has recently become available in Europe is glecaprevir/pibrentasvir (G/P). Numerous phase III-studies have shown its excellent effectiveness and tolerability across various patient populations including HIV-coinfected patients, individuals with renal impairment or other relevant comorbidities as well as patients with a history of previous treatment failure[
 <xref rid="pone.0229239.ref019" ref-type="bibr">19</xref>â€“
 <xref rid="pone.0229239.ref027" ref-type="bibr">27</xref>].
</p>
